Live Testing with Cannabix Marijuana Breathalyzer Shows Excellent Sensitivity for THC and Related Metabolites
March 27 2017 - 8:30AM
InvestorsHub NewsWire
7934 Government Road, Burnaby,
B.C., V5A 2E2
Phone: (604) 551-7831 Fax: 604-676-2767
info@cannabixtechnologies.com
cannabixtechnologies.com
The Cannabix Marijuana Breathalyzer is being developed to
give law enforcement and employers a tool to enforce public
safety
Vancouver, BC -- March 27, 2017 --InvestorsHub NewsWire --
Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the
“Company or Cannabix”) developer of the Cannabix Marijuana
Breathalyzer for law enforcement and the workplace, is pleased to
announce that preliminary human subject testing during the month of
March have produced excellent results. Cannabix is developing its
FAIMS- (field asymmetric waveform ion mobility spectrometry) based
marijuana breathalyzer for the detection of
delta-9-tetrahydrocannabinol (“THC”) in human breath. Testing using
the Cannabix Marijuana Breathalyzer Beta prototype device with
human subjects after smoking THC cigarettes demonstrated the
successful detection of THC, the psychoactive component of
marijuana, in real-time. In addition to THC, several metabolites
were identified in the breath of the human subjects including
11-hydroxy-delta-9-tetrahydrocannabinol and
delta-9-carboxy-tetrahydrocannabinol, and three other cannabinoids
related to cannabigerol, were confirmed by mass spectrometry after
the inhalation of cannabis.
The ability to detect THC and its metabolites in human breath is
a significant scientific breakthrough that allows for real-time
pharmacokinetic analysis. Such analysis provides a method for the
identification of frequent users of marijuana who tend to retain
THC in their body for longer periods of time, relative to
infrequent marijuana users who tend to clear THC from their body
more quickly.
The Company plans further testing with its Beta and Beta 2.0
prototypes over the coming weeks. The Company will be calibrating
decay signal intensities with a refined breath collection
component.
Dr. Bruce Goldberger, senior advisor to Cannabix, stated, “The
Cannabix Marijuana Breathalyzer utilizing FAIMS will allow the
Company to zero in on impairment with ‘recency of use’ like no
other currently known device out there.”
Dr. Raj Attariwala, commented, “The high resolving power of the
FAIMS device with its capability for real time detection of THC and
its metabolic breakdown products will aid in establishing key
metrics for measuring in-vivo THC metabolism and should permit
detection capabilities similar to that of blood tests. The current
human testing on of the FAIMS based Cannabix Marijuana Breathalyzer
has shown impressive results thus far.”
Rav Mlait, CEO commented, “This testing marks a major milestone
for the Company's research and development of the FAIMS technology
and will help guide the company in our goal in developing a device
that can detect levels of THC in the blood and correlate this with
the level of driver impairment.”
About Cannabix Technologies Inc.
Cannabix Technologies Inc. is a leader in marijuana breathalyzer
development for law enforcement and the workplace. Cannabix has
established breath testing technologies in the pursuit of bringing
durable, portable hand-held tools to market to enhance detection of
marijuana impaired driving offences on roads at a time when
marijuana is becoming legal in many global jurisdictions. Cannabix
is working to develop drug-testing devices that will detect THC-
the psychoactive component of marijuana that causes intoxication-
using breath samples. In particular, Cannabix is focused on
developing breath testing devices for detection of recent use of
THC, in contrast to urine testing for THC metabolite that requires
an invasive collection and reflects use days or even weeks earlier.
The devices will also be useful for other practical applications
such as testing employees in the workplace where intoxication by
THC can be hazardous.
We seek Safe Harbor.
On behalf of the Board of Directors
“Rav Mlait”
CEO
Cannabix Technologies Inc.
For further information, contact the Company at
info@cannabixtechnologies.com
The CSE has not reviewed and does not accept responsibility for
the adequacy or accuracy of this release.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking information that
involves various risks and uncertainties regarding future events.
Such forward-looking information can include without limitation
statements based on current expectations involving a number of
risks and uncertainties and are not guarantees of future
performance of the Company, such as final development of a
commercial or prototype product(s), successful trial or pilot of
company technologies, no assurance that commercial sales of any
kind actually materialize; no assurance the Company will have
sufficient funds to complete product development. There are
numerous risks and uncertainties that could cause actual results
and the Company’s plans and objectives to differ materially from
those expressed in the forward-looking information, including: (i)
adverse market conditions; (ii) risks regarding protection of
proprietary technology; (iii) the ability of the Company to
complete financings; (v) the ability of the Company to develop and
market its future product; and (vi) risks regarding government
regulation, managing and maintaining growth, the effect of adverse
publicity, litigation, competition and other factors which may be
identified from time to time in the Company's public announcements
and filings. There is no assurance that the marijuana breathalyzer
business will provide any benefit to the Company, and no assurance
that any proposed new products will be built or proceed. There is
no assurance that existing “patent pending” technologies licensed
by the Company will receive patent status by regulatory
authorities. The Company is not currently selling commercial
breathalyzers. Actual results and future events could differ
materially from those anticipated in such information. These and
all subsequent written and oral forward-looking information are
based on estimates and opinions of management on the dates they are
made and are expressly qualified in their entirety by this notice.
Except as required by law, the Company does not intend to update
these forward-looking statements.
Cannabix Technologies (CSE:BLO)
Historical Stock Chart
From Sep 2024 to Oct 2024
Cannabix Technologies (CSE:BLO)
Historical Stock Chart
From Oct 2023 to Oct 2024